Posted by Michael Wonder on 26 May 2017
Health Canada grants approval for Ocaliva (obeticholic acid) for the treatment of patients with primary biliary cholangitis
25 May 2017 - Ocaliva represents the first new treatment option in over 20 years for primary biliary cholangitis, an autoimmune liver disease that is the leading reason for liver transplantation in women in Canada.
Intercept Pharmaceuticals today announced that Health Canada has granted a conditional approval for Ocaliva (obeticholic acid) for the treatment of primary biliary cholangitis, when used in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA.
